A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

Organon and Co60 enrolled

Overview

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Paget's Disease of Bone

Interventions

alendronateDRUG

Duration of Treatment : 6 Months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease Exclusion Criteria: * Patient cannot stand or sit upright for at least 30 minutes * Patient has difficulty swallowing or problems with digestive system

Outcomes

Primary Outcomes

Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months

Secondary Outcomes

MK0217 will be safely tolerated

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.